other material
confidence high
sentiment positive
materiality 0.85
Lexeo reports Q3 2025 net loss $20.3M; FDA open to accelerated BLA for LX2006; raised $154M equity
Lexeo Therapeutics, Inc.
- FDA agreed to consider pooling ongoing Phase I/II LX2006 data with pivotal trial data for BLA; co-primary endpoint earlier than 12 months okayed.
- FDA approved comparability between HEK293 and Sf9 manufacturing processes for LX2006; Sf9 process endorsed for pivotal study.
- LX2006 interim data: 18-23% mean LVMI improvement at 6-12 months in abnormal-baseline patients; 2.0-point mean mFARS improvement (n=16).
- Enrollment complete for LX2020 HEROIC-PKP2 Phase I/II (10 dosed); substantive data update expected January 2026.
- Cash, equivalents, investments $122.8M at Sep 30, 2025; plus $153.8M net from October equity offering funds operations into 2028.